IRIS - Res&Arch Institutional Research Information System - Research & Archive

MANDALA', Mario
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.113
AS - Asia 5.087
EU - Europa 3.147
SA - Sud America 907
Continente sconosciuto - Info sul continente non disponibili 414
AF - Africa 125
OC - Oceania 13
Totale 15.806
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.946
SG - Singapore 2.787
RU - Federazione Russa 998
IE - Irlanda 719
BR - Brasile 689
IT - Italia 602
CN - Cina 596
HK - Hong Kong 581
VN - Vietnam 435
FR - Francia 256
DE - Germania 167
IN - India 107
KR - Corea 106
GB - Regno Unito 92
BD - Bangladesh 89
AR - Argentina 79
AT - Austria 62
CA - Canada 61
IQ - Iraq 57
MX - Messico 55
TR - Turchia 55
UA - Ucraina 50
FI - Finlandia 44
JP - Giappone 41
CO - Colombia 33
ES - Italia 30
PK - Pakistan 30
SA - Arabia Saudita 30
SE - Svezia 29
ZA - Sudafrica 29
VE - Venezuela 28
PL - Polonia 23
ID - Indonesia 21
NL - Olanda 21
PH - Filippine 21
CL - Cile 20
EC - Ecuador 20
EU - Europa 20
UZ - Uzbekistan 19
ET - Etiopia 14
JO - Giordania 13
KE - Kenya 13
EG - Egitto 12
GR - Grecia 12
MA - Marocco 12
MY - Malesia 12
CH - Svizzera 11
PY - Paraguay 11
UY - Uruguay 11
AE - Emirati Arabi Uniti 10
AU - Australia 10
PS - Palestinian Territory 10
TN - Tunisia 10
DZ - Algeria 9
AZ - Azerbaigian 8
CR - Costa Rica 8
PE - Perù 8
BO - Bolivia 7
HN - Honduras 7
IL - Israele 7
LT - Lituania 7
NP - Nepal 7
GE - Georgia 6
PA - Panama 6
CI - Costa d'Avorio 5
JM - Giamaica 5
KZ - Kazakistan 5
SN - Senegal 5
TW - Taiwan 5
LY - Libia 4
OM - Oman 4
RS - Serbia 4
TH - Thailandia 4
TT - Trinidad e Tobago 4
AL - Albania 3
BE - Belgio 3
CZ - Repubblica Ceca 3
DO - Repubblica Dominicana 3
LB - Libano 3
NI - Nicaragua 3
SV - El Salvador 3
SY - Repubblica araba siriana 3
BB - Barbados 2
BH - Bahrain 2
BZ - Belize 2
IR - Iran 2
MM - Myanmar 2
NG - Nigeria 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
PR - Porto Rico 2
PT - Portogallo 2
ZW - Zimbabwe 2
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BQ - ???statistics.table.value.countryCode.BQ??? 1
BW - Botswana 1
CG - Congo 1
CY - Cipro 1
Totale 15.387
Salva come PNG Salva come JPEG
Città #
Singapore 2.011
Chandler 944
San Jose 725
Dublin 718
Hong Kong 574
Ashburn 339
Santa Clara 302
Boardman 286
Dong Ket 273
Altamura 269
San Mateo 233
Lauterbourg 224
Medford 216
Moscow 213
Princeton 213
Lawrence 207
Andover 186
Los Angeles 154
Wilmington 121
Seoul 106
New York 84
São Paulo 63
Arezzo 57
Redwood City 57
Des Moines 52
Nuremberg 49
Ho Chi Minh City 48
Piscataway 48
Perugia 43
Norwalk 42
Beijing 40
San Paolo di Civitate 39
Tokyo 39
Shanghai 36
Hanoi 35
Chicago 32
The Dalles 31
Frankfurt am Main 29
Baghdad 25
Council Bluffs 25
Helsinki 25
Munich 24
Vienna 24
Milan 23
Redmond 23
Dallas 22
Hefei 22
Rio de Janeiro 22
Montreal 21
Brooklyn 19
San Francisco 19
Belo Horizonte 18
Brasília 18
Warsaw 18
Tianjin 17
Kocaeli 16
London 16
Columbus 15
Addis Ababa 14
Guangzhou 14
Jeddah 14
Mexico City 14
Rome 14
Saint Petersburg 14
Dhaka 13
Istanbul 13
Jacksonville 13
Johannesburg 13
Secaucus 13
Boston 12
Porto Alegre 12
Atlanta 11
Curitiba 11
Amman 10
Chennai 10
Haiphong 10
Nairobi 10
Santiago 10
Shijiazhuang 10
Denver 9
Falkenstein 9
Florence 9
Medellín 9
Montevideo 9
Quito 9
Tashkent 9
Turku 9
Bogotá 8
Da Nang 8
Guayaquil 8
Houston 8
Lahore 8
Manaus 8
Ribeirão Preto 8
Amsterdam 7
Asunción 7
Caxias do Sul 7
Charlotte 7
Islamabad 7
Jakarta 7
Totale 9.975
Salva come PNG Salva come JPEG
Nome #
Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action 131
Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial 112
Chemotherapy-associatedthromboembolic risk in cancer outpatients and effect of nadroparinthromboprophylaxis: results of a retrospective analysis of the PROTECHT study. 109
Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 triaL 105
Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial 102
Acquired and inherited risk factors for developing venous thromboembolism in cancer patients receiving adjuvant chemotherapy: a prospective trial 100
A prospective study on survival in cancer patients with and without venous thromboembolism. 99
Acute vulvar vestibulitis occurring during chemotherapy with cryptophycin analogue LY355703 96
A case of sudden brain metastases progression after temporary targeted therapy discontinuation: when to regret a drug holiday 96
Baseline β-catenin, programmed death-ligand 1 expression and tumour-infiltrating lymphocytes predict response and poor prognosis in BRAF inhibitor-treated melanoma patients 94
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma 92
Primary analysis and four-year follow-up of the phase III NIBIT-M2 trial in melanoma patients with brain metastases 92
Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism 92
Analysis of the Expression and Single-Nucleotide Variant Frequencies of the Butyrophilin-like 2 Gene in Patients With Uveal Melanoma 91
Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management 90
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma 90
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma 90
Abnormally enhanced blood concentrations of vascular endothelial growth factor (VEGF) in metastatic cancer patients and their relation to circulating dendritic cells, IL-12 and endothelin-1 90
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial 89
Adjuvant therapy in breast cancer and venous thromboembolism 88
Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF(V600E) or BRAF(V600K) mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial 88
Abrogation of the negative influence of opioids on IL-2 immunotherapy of renal cell cancer by melatonin 86
40. Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, Sun W, Jalal SI, Shah MA, Metges JP, Garrido M, Golan T, Mandala M, Wainberg ZA, Catenacci DV, Ohtsu A, Shitara K, Geva R, Bleeker J, Ko AH, Ku G, Philip P, Enzinger PC, Bang YJ, Levitan D, Wang J, Rosales M, Dalal RP, Yoon HH 84
Acute endocrine effects of interleukin-12 in cancer patients 83
Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial 82
Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival 82
Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling 81
Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i 80
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial 79
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial 79
Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria 76
ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee 75
Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab 74
Vinorelbine and carboplatin in inoperable non-small cell lung cancer: a monoinstitutional phase II study 74
Mitotic rate correlates with sentinel lymph node status and outcome in cutaneous melanoma greater than 1 millimeter in thickness: A multi-institutional study of 1524 cases 74
Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 74
BRAFV600 variant allele frequency predicts outcome in metastatic melanoma patients treated with BRAF and MEK inhibitors 73
Prophylaxis for venous thromboembolism in cancer patients with a central vein catheter: new tones for an old song 73
International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer 73
Acute dyspnea due to right phrenic palsy during infusional chemotherapy 72
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial 72
Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup 72
Clinicopathological predictors of recurrence in nodular and superficial spreading cutaneous melanoma: a multivariate analysis of 214 cases 72
Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility 72
Treatment of venous thromboembolism in cancer patients: The dark side of the moon 72
Insights Into Genetic Susceptibility to Melanoma by Gene Panel Testing: Potential Pathogenic Variants in ACD, ATM, BAP1, and POT1 71
PD-L1 up-regulation in melanoma increases disease aggressiveness and is mediated through miR-17-5p 71
Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study 71
Tissue prognostic biomarkers in primary cutaneous melanoma 70
Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis 70
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma 70
Vascular events with immune checkpoint inhibitors in melanoma or non-small cell lung cancer: A systematic review and meta-analysis 70
Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma 69
Melanoma brain metastases: review of histopathological features and immune-molecular aspects 69
Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172) 69
Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma 69
The density and spatial tissue distribution of CD8+ and CD163+immune cells predict response and outcome in melanoma patients receiving MAPK inhibitors 69
Wnt/β-catenin signaling in melanoma: Preclinical rationale and novel therapeutic insights 69
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238 68
Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. 68
An open-label, multicentre safety study of vemurafenib in patients with BRAF(V600)-mutant metastatic melanoma: final analysis and a validated prognostic scoring system 68
AKT-ions with a TWIST between EMT and MET 68
Acral lentiginous melanoma histotype predicts outcome in clinical stage I-II melanoma patients: an International multicenter study 67
Prevalence and Clinical Impact of SARS-CoV-2 Silent Carriers Among Actively Treated Patients with Cancer During the COVID-19 Pandemic 67
Targeting BRAF in melanoma: Biological and clinical challenges 67
Cutaneous toxicities of BRAF inhibitors: Clinical and pathological challenges and call to action 67
Impact of Circulating and Tissue Biomarkers in Adjuvant and Neoadjuvant Therapy for High-Risk Melanoma: Ready for Prime Time? 67
Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status 66
Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial 66
Association of socioeconomic status with Breslow thickness and disease-free and overall survival in stage I-II primary cutaneous melanoma 66
Dehydroepiandrosterone sulfate (DHEAS) secretion in early and advanced solid neoplasms: selective deficiency in metastatic disease 66
The extension of disease is associated to an increased risk of venous thromboembolism (VTE) in patients with gastrointestinal (GI) carcinoma 66
Efficacy of bromocriptine in the treatment of metastatic breast cancer- and prostate cancer-related hyperprolactinemia 66
European e-Delphi process to define expert consensus on electrochemotherapy treatment indications, procedural aspects, and quality indicators in melanoma 65
Is there a right-sided shift for colorectal cancer in women compared with men? 65
Immunomodulatory effects of IL-12 in relation to the pineal endocrine function in metastatic cancer patients 65
Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial 65
Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial 64
Body mass index (BMI) and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy: A multicenter international retrospective study 64
Venous thromboembolism and cancer: new issues for an old topic 64
Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma 64
Prognostic impact of baseline tumour immune infiltrate on disease-free survival in patients with completely resected, BRAFv600 mutation-positive melanoma receiving adjuvant vemurafenib 64
Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma 63
Buprenorphine-induced acute respiratory depression during ifosfamide-based chemotherapy 63
Dedifferentiated melanomas: Morpho-phenotypic profile, genetic reprogramming and clinical implications 63
Self-monitoring versus standard monitoring of oral anticoagulation 63
A case of severe pharyngeal-cervical-brachial syndrome induced by nivolumab and responding to infliximab therapy 63
Correlation of BRAF mutational status with clinical characteristics and survival outcomes of patients with ameloblastoma: the experience of 11 Italian centres 63
Multimodal treatment of advanced mucosal melanoma in the era of modern immunotherapy 62
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial 62
Adjuvant therapy of colon cancer. State of the art and future perspectives 62
GSTM1, P53 and K-ras molecular detection in resectable non-small cell lung cancer by denaturing gradient gel electrophoresis-bronchoalveolar lavage fluid analysis 62
mTORC1/autophagy-regulated MerTK in mutant BRAFV600 melanoma with acquired resistance to BRAF inhibition 62
Germline and somatic mutations in patients with multiple primary melanomas: a next generation sequencing study 62
International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer 62
Diagnostic and therapeutic approaches in Italian hospitals: adjuvant and metastatic therapy in melanoma 62
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study 62
Extracellular nicotinamide phosphoribosyltransferase (eNAMPT) is a novel marker for patients with BRAF-mutated metastatic melanoma 62
MelaNostrum: a consensus questionnaire of standardized epidemiologic and clinical variables for melanoma risk assessment by the melanostrum consortiuM 62
Targeting the PD1/PD-L1 axis in melanoma: Biological rationale, clinical challenges and opportunities 62
Totale 7.482
Salva come PNG Salva come JPEG
Categoria #
all - tutte 84.934
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 84.934
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.180 0 227 9 2 18 7 31 444 9 44 165 224
2022/20233.040 217 524 28 237 274 391 0 164 1.062 9 95 39
2023/2024981 90 154 53 28 18 5 143 9 96 122 99 164
2024/20253.186 34 296 24 82 406 143 92 136 1.173 258 285 257
2025/20266.505 644 444 267 492 841 527 1.223 529 586 652 202 98
2026/2027215 171 44 0 0 0 0 0 0 0 0 0 0
Totale 15.806